ERLONAT ERLOTINIB TABLETS IP

Get a Price/Quote

ERLONAT ERLOTINIB TABLETS IP Specification

Dosage Form
Tablets

Origin
India

Salt Composition
Erlotinib Hydrochloride

Feature
Orally administered, specific for EGFR mutations

Ingredients
Erlotinib Hydrochloride, excipients

Application
Oncology, targeted cancer therapy

Storage Instructions
Store below 30C, protect from light and moisture

Shelf Life
24 months

ERLONAT ERLOTINIB TABLETS IP Trade Information

Packaging Details
PACK OF 30 TABLETS

Main Domestic Market
All India

About ERLONAT ERLOTINIB TABLETS IP

Erlotinib Tablets

Specifications:-

Product Name:Erlonat
Contains:Erlotinib
Form:Tablet
Strength:25 mg, 100 mg & 150 mg
Packing:Pack Of 30 Tablets

NOTE:- Erlonat is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug...............

Precision Oncology for EGFR-Mutated Cancers

ERLONAT ERLOTINIB TABLETS IP target specific cancers by inhibiting epidermal growth factor receptor (EGFR) mutations, helping improve therapeutic outcomes in suitable patients. Their antineoplastic action provides a focused approach to managing certain types of solid tumors, particularly lung cancers.

Convenient Oral Administration and Storage

This medication is supplied as oral tablets for straightforward administration, enhancing patient compliance. Proper storagebelow 30C and protected from moisture and lightmaintains the stability and efficacy of Erlonat throughout its 24-month shelf life.

Strict Prescription and Distribution Standards

Erlonat is a prescription-only product, ensuring that its use is supervised by qualified healthcare professionals. Distributed and exported from India, these tablets meet international requirements and are accessible through licensed suppliers and traders.

FAQs of ERLONAT ERLOTINIB TABLETS IP:

Q: How should I take ERLONAT ERLOTINIB TABLETS IP?

A: These tablets are to be taken orally once daily, as prescribed by your oncologist. It is generally recommended to take the medication on an empty stomach, at least one hour before or two hours after eating, unless directed otherwise by your healthcare provider.

Q: What specific cancer types is Erlonat indicated for?

A: Erlonat is primarily prescribed for the treatment of non-small cell lung cancer and pancreatic cancer, particularly in patients with tumors exhibiting EGFR mutations. Always consult your oncologist to confirm its suitability for your condition.

Q: When should ERLONAT ERLOTINIB be stored and how?

A: Store ERLONAT tablets below 30C in a dry place, and keep them protected from light and moisture. It is important to avoid storage in humid or excessively warm environments to preserve the medications effectiveness.

Q: Where is ERLONAT ERLOTINIB manufactured and distributed?

A: ERLONAT ERLOTINIB TABLETS IP are manufactured in India and are available through licensed distributors, exporters, suppliers, and wholesalers, complying with national and international pharmaceutical standards.

Q: What is the benefit of targeted EGFR therapy with Erlonat?

A: Erlonats targeted action against EGFR mutations allows for personalized therapy, often resulting in improved outcomes for suitable patients with certain cancers compared to traditional chemotherapy protocols.

Q: What precautions should I follow during ERLONAT therapy?

A: Only use ERLONAT under medical supervision. Regular monitoring of treatment response and side effects is essential. Inform your doctor about other medications and report any unusual symptoms promptly.